FY26 task order to support NWI-omaha VA
Ended Awarded Last action
- Contract number
- 36C26326N0392
- Awardee
-
Veracyte, Inc. UEI JS7GBP6LCMN6
- Awarding agency
-
Veterans Integrated Service Network 23
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $67,600
Award facts
- Contract value 100% obligated
- $67,600.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- South San Francisco, CA 94080, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 23 (VISN 23), awarded a $67.6K delivery order to Veracyte, Inc. on May 1, 2026, for reference laboratory and genomic testing services supporting the NWI-Omaha VA facility. The order is structured as a firm fixed-price delivery order with a completion deadline of September 30, 2026, and carries no small business set-aside designation. This award is issued under Veracyte's existing $2M indefinite delivery/indefinite quantity (IDIQ) contract with VISN 23 for reference laboratory services, which runs through April 30, 2028, and has previously supported thyroid biopsy testing, reference laboratory services, and specialty genomic testing across VA facilities in northern and central California.
Veracyte, Inc., headquartered in South San Francisco, California, is a specialized medical diagnostic company providing proprietary molecular genomic testing services for precision medicine applications across federal healthcare systems. The company maintains an extensive federal contract portfolio serving the VA, Defense Health Agency, and Indian Health Service through multiple IDIQs and blanket purchase agreements under the GSA Medical Laboratory Testing and Analysis Services Federal Supply Schedule. Veracyte's core offerings include the Decipher Prostate Cancer Test for prostate cancer risk assessment and the Afirma Genomic Sequencing Classifier for thyroid nodule malignancy risk stratification, with recent contract awards ranging from approximately $12.9K to $1.85M across multiple VISN networks and other federal healthcare entities.
Quick answers
Who was awarded contract 36C26326N0392?
36C26326N0392 was awarded to Veracyte, Inc. by Veterans Integrated Service Network 23 (Veterans Health Administration) on May 1, 2026.
How much is contract 36C26326N0392 worth?
The government has obligated $67,600 on 36C26326N0392.
Is contract 36C26326N0392 an order under another contract?
Yes. 36C26326N0392 is a delivery order under 36C26323D0087, an indefinite delivery contract.
Was contract 36C26326N0392 competed?
The extent of competition for 36C26326N0392 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award